T follicular helper cell responses to SARS‐CoV‐2 vaccination among healthy and immunocompromised adults

Abstract

AbstractThe worldwide rollout of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccinations in the last 2 years has produced a multitude of studies investigating T‐cell responses in the peripheral blood and a limited number in secondary lymphoid tissues. As a key component to an effective immune response, vaccine‐specific T follicular helper (Tfh) cells are localized in the draining lymph node (LN) and assist in the selection of highly specific B‐cell clones for the production of neutralizing antibodies. While these cells have been noted in the blood as circulating Tfh (cTfh) cells, they are not often taken into consideration when examining effective CD4+ T‐cell responses, particularly in immunocompromised groups. Furthermore, site‐specific analyses in locations such as the LN have recently become an attractive area of investigation. This is mainly a result of improved sampling methods via ultrasound‐guided fine‐needle biopsy (FNB)/fine‐needle aspiration (FNA), which are less invasive than LN excision and able to be performed longitudinally. While these studies have been undertaken in healthy individuals, data from immunocompromised groups are lacking. This review will focus on both Tfh and cTfh responses after SARS‐CoV‐2 vaccination in healthy and immunocompromised individuals. This area of investigation could identify key characteristics of a successful LN response required for the prevention of infection and viral clearance. This furthermore may highlight responses that could be fine‐tuned to improve vaccine efficacy within immunocompromised groups that are at a risk of more severe disease.